moneyheap
ABBV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is AbbVie Inc. (ABBV) stock moving?
ABBV closed at $293.89 on Nov 10, up from about $285 on Oct 22 and recovering from a $286 close on Nov 3. The stock rose to $294.89 after the Oct 30 Q3 report, which included revenue and EPS beats, then fell 2% on Nov 2 on heavy volume of 8.9M shares. It hit an intraday high of $302.93 on Nov 5 and has since held in the $288–295 range. Volume has faded to about 3.5M shares, below the recent 5–9M average, so the rebound is not showing strong buying pressure. Analyst sentiment turned clearly positive: Morgan Stanley ($346), Wells Fargo ($340), Guggenheim ($322), and Argus ($320) all lifted targets, while UBS's Neutral $295 target sits near the current price. Pipeline and deal flow is active, with the Brise migraine license (up to $757M per fiscal.ai; Benzinga reports $775M), the Nxera IBD license, and ASH data readouts ahead in December. The Allergan HALO interim result rests on only 25 patients, and a board resignation is a minor governance item. Market-cap context is about $510B per Benzinga.
News behind the analysis
- Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $346Morgan Stanley kept its Overweight rating on AbbVie and raised its price target to $346 after the Q3 print.
- Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $340Wells Fargo kept its Overweight rating on AbbVie and lifted its price target to $340.
- AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To ReaccelerateAbbVie shares fell 2% despite Q3 revenue and EPS beats, and analysts raised targets on immunology strength and long-term growth.
- Argus Research Adjusts Price Target on AbbVieArgus Research raised its AbbVie price target from $270 to $320.
- UBS Maintains Neutral on AbbVie, Raises Price Target to $295UBS kept a Neutral rating on AbbVie and raised its price target to $295, close to the current share price.
- AbbVie Enters Global License Agreement with Brise Pharmaceuticals for Migraine TherapiesAbbVie licensed two preclinical migraine programs from Brise Pharmaceuticals, with a potential deal value of up to $757 million.
- AbbVie Enters Global License Agreement with Nxera Pharma for IBD Drug CandidateAbbVie secured exclusive global rights to Nxera Pharma's EP4 receptor agonist NXE0033744 for inflammatory bowel disease.
- Genmab and AbbVie to Present Epcoritamab Data at ASH Annual MeetingGenmab and AbbVie will present 22 abstracts, including Phase 3 epcoritamab data, at the 68th ASH Annual Meeting.
- Allergan Aesthetics Announces Results from Phase 4 Studies on Aesthetic Treatments for GLP-1 PatientsAllergan Aesthetics, an AbbVie company, reported positive Phase 4 results on patient satisfaction with facial appearance after aesthetic treatments in patients on GLP-1 medications.
- AbbVie Director Jennifer L. Davis Resigns from BoardDirector Jennifer L. Davis resigned from AbbVie's board effective November 2, 2026.
About ABBVIE INC.
AbbVie is a large US drugmaker, spun off from Abbott Laboratories in 2013. It is best known for immunology drugs. After its former blockbuster Humira lost US patent protection, its newer drugs Skyrizi and Rinvoq took over most of that growth.
How it makes money
AbbVie makes money by selling prescription drugs and aesthetic treatments. Its 2025 revenue was roughly $61 billion. Immunology is the biggest part, at roughly half of sales: Skyrizi alone is expected to bring in about $22 billion in 2026 and Rinvoq about $10 billion, while Humira sales keep falling. Other sources are neuroscience drugs (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta), cancer drugs (Venclexta, Imbruvica, Epkinly, Elahere) and aesthetics (Botox Cosmetic, Juvederm).
What usually moves ABBV
- Skyrizi and Rinvoq sales growth and new approved uses
- Falling Humira sales as cheaper copycat versions (biosimilars) compete
- Clinical trial results and acquisitions, such as the roughly $11 billion Apogee deal
- US drug pricing rules and Medicare price negotiation
- Consumer demand for aesthetics like Botox Cosmetic